联系方式：400-650-8506
CNEN
产品名称 FRAX 486
产品货号 Axon 2331 CAS [1232030-35-1] MF C25H23Cl2FN6OMW 513.39 Purity: 99% Soluble in DMSO Description Bioavailable and brain penetrating inhibitor of group I p21-activated kinases (IC50 values 8.25 nM, 39.5 nM, and 55.3 nM for PAK1, PAK2, and PAK3, respectively) with good selectivity over PAK4 (IC50 value 779 nM) FRAX486 rescues the dendritic spine abnormality and audiogenic seizures, and reduces autism-like phenotypes of hyperactivity and restrictive or repetitive behaviors in Fmr1 KO mice. Not only represents FRAX-486 a potential breakthrough in the research for a treatment of Fragile X syndrome (FXS), it was also found to ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. References Certificates Categories Extra info B.M. Dolan et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5671-6.   A. Hayashi-Takagi et al. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6461-6. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Signaling & Oncology CNS Immunology Pain & Inflammation EC 2.7.11.1 PAK Bioavailable, brain penetrating inhibitor of p21-activated kinases (PAKs) Chemical name 6-(2,4-dichlorophenyl)-8-ethyl-2-(3-fluoro-4-(piperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one Parent CAS No. [1232030-35-1] Order Size Unit Price Stock 5 mg €90.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

FRAX 486

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2331

CAS [1232030-35-1]

MF C25H23Cl2FN6O
MW 513.39

  • Purity: 99%
  • Soluble in DMSO

FRAX 486

Description

Bioavailable and brain penetrating inhibitor of group I p21-activated kinases (IC50 values 8.25 nM, 39.5 nM, and 55.3 nM for PAK1, PAK2, and PAK3, respectively) with good selectivity over PAK4 (IC50 value 779 nM) FRAX486 rescues the dendritic spine abnormality and audiogenic seizures, and reduces autism-like phenotypes of hyperactivity and restrictive or repetitive behaviors in Fmr1 KO mice. Not only represents FRAX-486 a potential breakthrough in the research for a treatment of Fragile X syndrome (FXS), it was also found to ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence.
产品资料